BAM
RVMD icon

Bellevue Asset Management’s Revolution Medicines RVMD Stock Holding History

Bellevue Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
+700
New +$102K 0.06% 104
2026
Q1 		– Sell
-25
Closed -$1.99K – 475
2025
Q4 		$1.99K Hold
25
– – ﹤0.01% 437
2025
Q3 		$1.17K Buy
+25
New +$979 ﹤0.01% 480

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bellevue Asset Management's RVMD Position: Q2 2026 in Review

Bellevue Asset Management opened a new position in Revolution Medicines (RVMD) in Q2 2026: 700 shares worth $131K. The stake represents 0.06% of the portfolio and ranks #104 among its holdings. This is a return to the name: Bellevue Asset Management previously reported a position in RVMD as recently as Q4 2025.

Bellevue Asset Management first reported a position in RVMD in Q3 2025 and has held it in 3 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Bellevue Asset Management held 700 shares of Revolution Medicines worth $131K as of Q2 2026.
  • Revolution Medicines was a new Bellevue Asset Management position in Q2 2026.
  • Revolution Medicines made up 0.06% of Bellevue Asset Management's portfolio in Q2 2026, its #104 holding.
  • Bellevue Asset Management first reported a position in Revolution Medicines in Q3 2025 and has held it in 3 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Bellevue Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.